Dr. Anthony P.D. Ford, Ph.D. co-founded Afferent Pharmaceuticals, Inc. in 2009 and served as its Chief Scientific Officer until it’s take over by Merck in 2016.Dr. Ford has more than 20 years of research and development experience at Roche (where he served as Vice President) Syntex and Afferent, having led the progression of several novel drug candidates into early clinical development, focused particularly in the areas of pain and genitourinary therapeutics. He was also responsible for the development of AF-219, a selective P2X3 antagonist for the treatment of pathologic cough. Dr. Ford was trained in neuropharmacology and holds a Ph.D. from the University of Nottingham (UK).